TARGET AUDIENCE
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

OVERVIEW OF ACTIVITY
The pace of oncology drug development has accelerated in recent years to previously unmatched levels. Fueled by an increased understanding of the biologic underpinnings of tumor development and disease progression, clinical research platforms largely focused on evaluating the potential benefits of novel targeted agents with unique mechanisms of action and safety profiles have led to improved outcomes in myriad large and rigorous clinical trials across many different cancer types. The successes yielded by this rational approach to the design and evaluation of new therapies have in turn provided oncology healthcare professionals and patients with many additional and beneficial FDA-endorsed treatment options. In particular, a plethora of extremely promising data sets have emerged relating to the use of immunotherapy and other novel agents in the management of gynecologic cancers (ovarian, cervical and endometrial cancer). Existing management algorithms for these diseases are poised for further change, and it is critical that continuing education be offered to all practitioners involved in patient care.

This CME program developed from a virtual satellite symposium originally planned for the 2020 SGO Annual Meeting features discussions with leading gynecology oncology investigators regarding cases from their practices, survey results and published data that drive clinical decision-making. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, gynecologic oncologists and other healthcare providers with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Describe the biologic rationale for, published research data with and ongoing evaluation of immune checkpoint inhibitors in the management of ovarian, endometrial and cervical cancer, and identify patients who may be eligible for this strategy in or outside of a clinical research setting.
• Appraise the clinical research findings supporting the FDA approval of anti-PD-1 monotherapy for PD-L1-positive, progressive metastatic cervical cancer, and counsel appropriate patients about the risks and potential benefits of this treatment approach.
• Recall available data with and ongoing investigation of anti-PD-1/PD-L1 antibodies, either alone or in combination with other targeted agents, for patients with gynecologic cancers.
• Design and implement a plan of care to recognize and manage side effects and toxicities associated with immune checkpoint inhibitors in the management of ovarian, endometrial and cervical cancer in order to support quality of life and continuation of therapy.
• Review the mechanisms of action, emerging efficacy data and toxicity profiles of novel antibody-drug conjugates under investigation for advanced cervical cancer.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THESE CME ACTIVITIES
Audio Program: This CME activity consists of an audio component.
CME credit is no longer available for this issue

Video Program: This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Michael J Birrer, MD, PhD
Director, Winthrop P Rockefeller Cancer Institute
Director, Cancer Service Line
University of Arkansas
Little Rock, Arkansas

Consulting Agreements: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Tesaro, A GSK Company.

Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine 
Harvard Medical School 
Boston, Massachusetts

Advisory Committee and Consulting Agreement: Novartis.

David M O’Malley, MD
Professor
Division Director, Gynecologic Oncology
Co-Director, Gynecologic Oncology Phase I Program
The Ohio State University and The James Cancer Center
Columbus, Ohio

Advisory Committee: AbbVie Inc, Agenus Inc, Ambry Genetics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genelux, Genentech, a member of the Roche Group, GOG Foundation Inc, ImmunoGen Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Merck, Myriad Genetic Laboratories Inc, Novocure, Regeneron Pharmaceuticals Inc, Tarveda Therapeutics, Tesaro, A GSK Company; Consulting Agreements: AbbVie Inc, Agenus Inc, Ambry Genetics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Genmab, GOG Foundation Inc, ImmunoGen Inc, Novocure, Regeneron Pharmaceuticals Inc, Seattle Genetics, Tesaro, A GSK Company; Contracted Research: AbbVie Inc, Agenus Inc, Ajinomoto Co Inc, Amgen Inc, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Daré Bioscience, Eisai Inc, EMD Serono Inc, Ergomed Plc, Genentech, a member of the Roche Group, Genmab, GlaxoSmithKline, GOG Foundation Inc, ImmunoGen Inc, Iovance Botherapeutics Inc, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Ludwig Institute for Cancer Research Ltd, Merck, New Mexico Cancer Care Alliance, Novocure, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Seattle Genetics, Stemcentrx, Syneos Health, Tesaro, A GSK Company, TRACON Pharmaceuticals Inc, VentiRx Pharmaceuticals Inc. Data and Safety Monitoring Board/Committee: Marker Therapeutics Inc.

Krishnansu S Tewari, MD
Professor and Division Director
Division of Gynecologic Oncology
University of California, Irvine
Irvine, California

Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Tesaro, A GSK Company; Contracted Research (institution only): AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Merck, Roche Laboratories Inc, Tesaro, A GSK Company.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Eisai Inc, Merck, Seattle Genetics and Tesaro, A GSK Company.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: July 2020
Expiration date: July 2021